Prevention of nausea and vomiting associated with chemotherapy

Indication for Aprepitant

Population group: Suitable for both men and women, only adults (18 years old or older)
Therapeutic intent: Preventive action

Prevention nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adults.

For this indication, competent medicine agencies globally authorize below treatments:

80-125 mg once daily

Route of admnistration

Oral

Defined daily dose

80 - 125 mg

Dosage regimen

From 80 To 125 mg once every day

Loading dose

125 mg

Maintenance dose

80 mg

Detailed description

Aprepitant is given for 3 days as part of a regimen that includes a corticosteroid and a 5-HT3 antagonist. The recommended dose is 125 mg orally once daily one hour before start of chemotherapy on Day 1 and 80 mg orally once daily on Days 2 and 3 in the morning

The following regimens are recommended in adults for the prevention of nausea and vomiting associated with emetogenic cancer chemotherapy.

Highly Emetogenic Chemotherapy Regimen:

 Day 1Day 2Day 3Day 4
Aprepitant125 mg orally80 mg orally80 mg orallynone
Dexamethasone12 mg orally8 mg orally8 mg orally8 mg orally
5-HT3 antagonistsStandard dose of 5-HT3 antagonists. See the product information for the selected 5-HT3 antagonist for ppropriate dosing nformationnonenonenone

Dexamethasone should be administered 30 minutes prior to chemotherapy treatment on Day 1 and in the morning on Days 2 to 4. The dose of dexamethasone accounts for active substance interactions.

Moderately Emetogenic Chemotherapy Regimen:

 Day 1Day 2Day 3
Aprepitant125 mg orally80 mg orally80 mg orally
Dexamethasone12 mg orallynonenone
5-HT3 antagonistsStandard dose of 5-HT3 antagonists. See the product information for the selected 5-HT3 antagonist for appropriate dosing informationnonenone

Dexamethasone should be administered 30 minutes prior to chemotherapy treatment on Day 1. The dose of dexamethasone accounts for active substance interactions.

Active ingredient

Aprepitant is a selective high-affinity antagonist at human substance P neurokinin 1 (NK1) receptors.

Read more about Aprepitant

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner